Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ERNA
ERNA | US
0.27
USD-0.00
-1.59%
ERNA | US
About ERNA
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
20/03/2026
Close
0.27
Open
0.28
High
0.28
Low
0.26
Eterna Therapeutics Inc. a preclinical-stage biopharmaceutical company. The company offers Synthetic mRNA ToRNAdo mRNA Delivery mRNA Gene Editing and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology blood disorder and monogenic disease. The company was formerly known as and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Cambridge Massachusetts.
View LessERNA | US
Risk
109.7
Sharpe
-0.84
Luna's Score
39/100
Recommendation
Sell
Luna says (ERNA | US)
What's Working
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
86.7%1 month
109.7%3 months
147.9%6 months
134.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.10
Debt to equity
-5.77
Debt to assets
1.06
Ent. to EBITDA
-0.29
Ent. to rev.
321.84
PEG
-
Other Fundamentals
EBITDA
-21.86M
MarketCap
1.44M
MarketCap(USD)
1.44M
Div. yield
-
Op. margin
-10.49K
Erngs. growth
-
Rev. growth
-
Ret. on equity
-1.15K
Short ratio
1.01
Short perc.
1.32
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.09
Range1M
0.14
Range3M
1.14
Volumes: Market Activity
Rel. volume
0.98
Price X volume
420.37K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.29 | - | Cheaper |
| Ent. to Revenue | 321.84 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.10 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 147.86 | - | Riskier |
| Debt to Equity | -5.77 | -1.23 | Cheaper |
| Debt to Assets | 1.06 | 0.25 | Expensive |
| Market Cap | 1.44M | - | Emerging |
